
From-STOEL RIVES LLP





600 University Street, Suite 3600 Seattle, Washington, 98101 main 206.624.0900 fax 206.386.7500 www.stocl.com

| | Name: | Fax No. | Company/Firm | Phone No. |
|---|--|-------------------------|-------------------------|---|
| TO: | David S. Romeo | (571) 273-0890 | USPTO | |
| | Name: | Sender's | Direct Dial: | Sender's Direct Email: |
| FROM: | Samuel E. Webb | (206) 386-7683 | | sewebb@stoel.com |
| Client: | 38263 | - | Matter: 19 | |
| Date: | May 12, 2009 | | | |
| No. of Pages (including this cover): 5 | | | | |
| Originals Not Forwarded Unless Checked: First Class Mail Overni ght Delivery Hand Deli very | | | | |
| In case of error, call the fax operator at (206) 386-7506. | | | | |
| of this mes | nile may contain confidential i sage is not the intended recip notify us immediately by teleph | ient or an employee re. | sponsible for deliverir | lient or work product privilege. If the reader ng the fucsimile, please do not distribute this you. |
| COMM | | | | |
| Re Application No. 10/519,342 for Li, et al. | | | | |

PROPOSED DRAFT FOR INTERVIEW DISCUSSION PURPOSES ONLY DO NOT ENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. ; 10/519,342 Confirmation No. 2504

Applicant : Li et al.

Title : METHODS AND COMPOSITIONS FOR

MANIPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS

Filed: September 21, 2005

TC/A.U. : 1647

Examiner : David S. Romeo

Docket No. : 38263/19

Customer No. : 32642

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PROPOSED DRAFT AMENDMENT

Dear Sir:

In response to the Office Action of February 19, 2009, please amend the aboveidentified application as follows:

The Listing of Claims begins on page 2 of this paper.

Appl, No.10/519,342 DRAFT Amdt. dated May 12, 2009 FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claim in the application:

Listing of Claims:

Claims 1 through 6 canceled.

- 7. (Currently Amended) A method of preventing guided navigation of endothelial tubes during angiogenesis to a target cell mass inhibiting migration human microvascular endothelial cells (HMVECs) expressing a native Robo-4 receptor, wherein said endothelial tubes express a Robo 4 receptor, the method comprising activating said Robo-4 receptor, wherein activating said Robo-4 receptor exposing said HMVECs to a Slit ligand, wherein exposing said HMVECs to said Slit ligand inhibits the guided navigation of the endothelial tubes toward the target cell mass migration of said HMVECs.
- 8. (Currently Amended) The method of claim 7, wherein activating said Robo-4 receptor comprises providing-a-ligand capable of activating said-Robo-4 receptor and exposing-said-endothelial tubes to the ligand, wherein said exposure of said-endothelial tubes to said ligand-inhibits the guided navigation of the endothelial tubes toward the target-cell-mass exposing said HMVECs to a Slit ligand comprises exposing said HMVECs to a Slit2 ligand.
- 9. (Currently Amended) The method of claim 8, wherein providing a ligand capable of activating said Robo-4-receptor comprises providing a Slit exposing said HMVECs to a Slit2 ligand comprises exposing said HMVECs to a human Slit2 ligand or a fragment thereof.

Claims 10 through 18 canceled.

Page 2 of 4

K:\Navigen\19\2A095734.tmp

Appl. No.10/519,342 DRAFT Amdt. dated May 12, 2009 FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER

- 19. (Currently Amended) A method of preventing angiogenesis in endothelium tissue expressing Robo 4-receptor, the method comprising, activating said Robo-4 receptor, wherein-activating said Robo-4 receptor inhibits migration of endothelial-sells inhibiting migration of HMVECs expressing a native Robo-4 receptor, wherein inhibiting migration of said HMVECs comprises providing a Slit ligand and exposing said HMVECs to said Slit ligand such that migration of said HMVECs is inhibited
- 20. (Currently Amended) The method of claim 19, wherein activating said Robo-4 receptor-comprises providing-a-ligand capable of activating said-Robo-4 receptor and exposing-the endothelium tissue to the ligand, wherein said exposure-of said endothelium tissue-to-said ligand inhibits-migration of endothelial cells providing a Slit ligand comprises providing a Slit ligand.
- 21. (Currently Amended) The method of claim 20, wherein providing a ligand capable-of activating said Robo 4-receptor providing a Slit2 ligand comprises providing a Slit ligand providing a human Slit2 ligand or a fragment thereof.

Claim 22 canceled.

Appl. No.10/519,342 DRAFT Amdt. dated May 12, 2009 FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER

Respectfully submitted,

Samuel E. Webb Reg. No. 44,394 Attorney for Applicant

Date: May 12, 2009

STOEL RIVES LLP 600 University Street, Suite 3600 Seattle, WA 98101

Telephone: (206) 386-7683 Facsimile: (206) 386-7500